Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-cell transcriptomics of alloreactive CD4+ T cells over time reveals divergent fates during gut graft-versus-host disease
Jessica A. Engel, Hyun Jae Lee, Cameron G. Williams, Rachel Kuns, Stuart Olver, Lianne I.M. Lansink, Megan S.F. Soon, Stacey B. Andersen, Joseph E. Powell, Valentine Svensson, Sarah A. Teichmann, Geoffrey R. Hill, Antiopi Varelias, Motoko Koyama, Ashraful Haque
Jessica A. Engel, Hyun Jae Lee, Cameron G. Williams, Rachel Kuns, Stuart Olver, Lianne I.M. Lansink, Megan S.F. Soon, Stacey B. Andersen, Joseph E. Powell, Valentine Svensson, Sarah A. Teichmann, Geoffrey R. Hill, Antiopi Varelias, Motoko Koyama, Ashraful Haque
View: Text | PDF
Research Article Hematology Immunology

Single-cell transcriptomics of alloreactive CD4+ T cells over time reveals divergent fates during gut graft-versus-host disease

  • Text
  • PDF
Abstract

Acute gastrointestinal (GI) graft-versus-host disease (GVHD) is a primary determinant of mortality after allogeneic hematopoietic stem cell transplantation (alloSCT). The condition is mediated by alloreactive donor CD4+ T cells that differentiate into pathogenic subsets expressing IFN-γ, IL-17A, or GM-CSF and is regulated by subsets expressing IL-10 and/or Foxp3. Developmental relationships between Th cell states during priming in mesenteric lymph nodes (mLNs) and effector function in the GI tract remain undefined at genome scale. We applied scRNA-Seq and computational modeling to a mouse model of donor DC-mediated GVHD exacerbation, creating an atlas of putative CD4+ T cell differentiation pathways in vivo. Computational trajectory inference suggested emergence of pathogenic and regulatory states along a single developmental trajectory in mLNs. Importantly, we inferred an unexpected second trajectory, categorized by little proliferation or cytokine expression, reduced glycolysis, and high tcf7 expression. TCF1hi cells upregulated α4β7 before gut migration and failed to express cytokines. These cells exhibited recall potential and plasticity following secondary transplantation, including cytokine or Foxp3 expression, but reduced T cell factor 1 (TCF1). Thus, scRNA-Seq suggested divergence of alloreactive CD4+ T cells into quiescent and effector states during gut GVHD exacerbation by donor DC, reflecting putative heterogeneous priming in vivo. These findings, which are potentially the first at a single-cell level during GVHD over time, may assist in examination of T cell differentiation in patients undergoing alloSCT.

Authors

Jessica A. Engel, Hyun Jae Lee, Cameron G. Williams, Rachel Kuns, Stuart Olver, Lianne I.M. Lansink, Megan S.F. Soon, Stacey B. Andersen, Joseph E. Powell, Valentine Svensson, Sarah A. Teichmann, Geoffrey R. Hill, Antiopi Varelias, Motoko Koyama, Ashraful Haque

×

Figure 7

TCF1hi TEa T cells can mount secondary effector responses in vivo.

Options: View larger image (or click on image) Download as PowerPoint
TCF1hi TEa T cells can mount secondary effector responses in vivo.
(A) S...
(A) Schematic of secondary TEa transfer experiment. On day 4 of the primary transplant, CD25–CXCR6– or CD25+ and/or CXCR6+ (referred to as CD25+CXCR6+) TEa were FACS isolated from mLN. A total of 0.8 × 106 CD25–CXCR6– and 0.4 × 106 CD25+CXCR6+ TEa (or control 0.8 × 106 naive TEa) were transferred into recipient BALB/c mice that had received total body irradiation and a bone marrow transplant 13 and 12 days prior, respectively. FACS assessment of mLN TEa cells was performed on day 4 or 5 after secondary transfer. (B) Absolute numbers of TEa cells in the mLN at day 4 or 5 after secondary transfer. Arrows along the y-axis denote the number of TEa cells that were transferred per mouse for each group on day 0 (0.8 × 106 naive TEa (gray) and CD25–CXCR6– TEa (turquoise), 0.4 × 106 CD25+CXCR6+ TEa (purple). (C) Representative flow cytometry plots showing the expression of T-bet and Tcf1 on TEa cells from the mLN at day 4 or 5 after secondary transfer. The graph shows the percentage of TEa cells that are Tcf1lo or Tcf1hi in each group. (D and E) Representative FACS plots showing IFN-γ, IL-17A, and Foxp3 expression on TEa cells after secondary transfer on day 4 or 5 from the mLN directly ex vivo (D) or after restimulation with PMA and ionomycin (E). Graphs show the percentage of IFN-γ+, IL-17A+, and Foxp3+ TEa for each group. Data shown are combined from 2 independent experiments showing similar results (B–D: naive, n = 12; CD25–CXCR6–, n= 7, and CD25+CXCR6+, n = 6) or from one experiment only (E: naive, n = 6; CD25–CXCR6–, n= 4). Data are shown as the median (B) or mean ± SEM (C–E). Statistical analysis was performed using a Mann-Whitney test (B, D, and E) or a paired t test (C). *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts